Antonio M. Benitz

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.

Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA.